Sign in

Cyclosporine approved

1983Big moment

Cyclosporine, a fungal compound that suppresses rejection, is approved in the U.S., making liver, heart and lung transplants routine.

The story

In November 1983 the U.S. Food and Drug Administration approved cyclosporine, sold by the Swiss company Sandoz as Sandimmune, as a drug to prevent organ rejection. Its approval transformed organ transplantation from a risky experiment with poor odds of long-term success into a routine treatment. Liver, heart and lung transplants, which had mostly failed with earlier drugs, became realistic options for thousands of patients each year.

The central problem of transplantation is rejection: the recipient's immune system recognizes the new organ as foreign and attacks it. The first successful kidney transplant, between identical twins in 1954, avoided the problem, since twins are genetically alike. For other patients doctors relied on drugs such as azathioprine and steroids, which suppressed the whole immune system bluntly, left patients open to deadly infection and still allowed many grafts to fail. A drug that quieted the specific immune cells attacking the organ was needed.

Cyclosporine came from a fungus, Tolypocladium inflatum, found in a soil sample in Norway. In 1972 Jean-Francois Borel at Sandoz in Basel discovered that the compound was a powerful immunosuppressant, even though it did little against fungi. It blocks a signaling enzyme called calcineurin in T cells, preventing them from launching an attack. Roy Calne in Cambridge tested it in kidney transplants in 1978, and Thomas Starzl in Pittsburgh used it in liver transplants, showing much better survival. After its approval, heart transplants at Stanford and elsewhere also began to succeed far more often. Cyclosporine has side effects, including kidney damage, and was later joined by drugs such as tacrolimus, but it opened the modern era of transplantation.

Why it mattered

  • Heart, liver and lung transplants became established treatments, with survival rates far above the pre-cyclosporine years.
  • Kidney transplant success rose, with fewer grafts rejected in the first year.
  • Transplant medicine expanded into a large field, with donor registries, matching systems and new immunosuppressive drugs.
  • The success of a natural product from soil fungus encouraged the search for drugs in microbes around the world.

Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made

Community notes

Loading notes…

Learn more ranked by votes

BookRenée C. Fox and Judith P. Swazey
Spare Parts: Organ Replacement in American Society
Search Open Library
VideoSearch YouTube
cyclosporine transplant history
Search YouTube